未名医药
(002581)
| 流通市值：50.46亿 | | | 总市值：83.06亿 |
| 流通股本：4.01亿 | | | 总股本：6.60亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 338,346,310.25 | 209,166,285.01 | 75,602,502.59 | 357,080,537.01 |
| 营业收入 | 338,346,310.25 | 209,166,285.01 | 75,602,502.59 | 357,080,537.01 |
| 利息收入 | 0 | 0 | - | - |
| 已赚保费 | 0 | 0 | - | - |
| 手续费及佣金收入 | 0 | 0 | - | - |
| 二、营业总成本 | 430,315,379.45 | 283,687,805.59 | 104,535,537.78 | 543,471,899.28 |
| 营业成本 | 63,753,492.13 | 39,874,646.67 | 14,582,127.66 | 76,211,562.74 |
| 利息支出 | 0 | 0 | - | - |
| 手续费及佣金支出 | 0 | 0 | - | - |
| 退保金 | 0 | 0 | - | - |
| 赔付支出净额 | 0 | 0 | - | - |
| 提取保险合同准备金净额 | 0 | 0 | - | - |
| 保单红利支出 | 0 | 0 | - | - |
| 分保费用 | 0 | 0 | - | - |
| 税金及附加 | 5,114,307.59 | 3,346,616.23 | 966,548.65 | 6,459,049.55 |
| 销售费用 | 213,415,376.32 | 136,361,700.09 | 49,790,563.52 | 292,477,634.84 |
| 管理费用 | 102,013,007.06 | 70,112,424.78 | 27,980,380.3 | 133,729,490.27 |
| 研发费用 | 38,701,789.18 | 28,744,051.61 | 8,327,976.44 | 27,289,010.45 |
| 财务费用 | 7,317,407.17 | 5,248,366.21 | 2,887,941.21 | 7,305,151.43 |
| 其中:利息费用 | 0 | 0 | - | 10,263,261.49 |
| 其中:利息收入 | 0 | 0 | - | 3,022,500.23 |
| 加:公允价值变动收益 | 0 | 0 | - | - |
| 加:投资收益 | 144,096,951.61 | 36,080,828.76 | 6,622,813.82 | 217,454,111.69 |
| 净敞口套期收益 | 0 | 0 | - | - |
| 汇兑收益 | 0 | 0 | - | - |
| 资产处置收益 | -6,548,648.35 | -5,682,142.97 | 291,408.45 | 51,479.46 |
| 资产减值损失(新) | -8,331,413.89 | -8,331,413.89 | - | -13,990,028.37 |
| 信用减值损失(新) | 1,021,410.87 | 959,267.57 | 262,988.02 | 4,866,275.03 |
| 其他收益 | 6,355,937.91 | 1,038,401.27 | 609,761.88 | 11,680,998.33 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 44,625,168.95 | -50,456,579.84 | -21,146,063.02 | 33,671,473.87 |
| 加:营业外收入 | 45,355.73 | 14,355.7 | 30,593.43 | 32,602.3 |
| 减:营业外支出 | 1,984,239.23 | 975,707.13 | 339,933.07 | 20,979,419.19 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 42,686,285.45 | -51,417,931.27 | -21,455,402.66 | 12,724,656.98 |
| 减:所得税费用 | 4,157,780.88 | -564,750.49 | -76,304.06 | 13,592,847.77 |
| 六、净利润 | 38,528,504.57 | -50,853,180.78 | -21,379,098.6 | -868,190.79 |
| 持续经营净利润 | 38,528,504.57 | -50,853,180.78 | -21,379,098.6 | -868,190.79 |
| 归属于母公司股东的净利润 | 29,713,342.05 | -53,757,277.48 | -21,505,965.06 | -14,689,829.85 |
| 少数股东损益 | 8,815,162.52 | 2,904,096.7 | 126,866.46 | 13,821,639.06 |
| (一)基本每股收益 | 0.05 | -0.08 | -0.03 | -0.02 |
| (二)稀释每股收益 | 0.05 | -0.08 | -0.03 | -0.02 |
| 九、综合收益总额 | 38,528,504.57 | -50,853,180.78 | -21,379,098.6 | -868,190.79 |
| 归属于母公司股东的综合收益总额 | 29,713,342.05 | -53,757,277.48 | -21,505,965.06 | -14,689,829.85 |
| 归属于少数股东的综合收益总额 | 8,815,162.52 | 2,904,096.7 | 126,866.46 | 13,821,639.06 |
| 公告日期 | 2023-10-31 | 2023-08-31 | 2023-04-27 | 2023-04-27 |
| 审计意见(境内) | | | | 保留意见 |